Exact Sciences Corp EXAS

Founded in 1995, Exact Sciences Corp is a molecular diagnostics company that provides early detection products for a variety of cancers. Originally located in Marlborough, Massachusetts, Exact Sciences Corp is headquartered in Madison, Wisconsin. It supplies its products to customers in the US and globally.

Exact Sciences' current product range is concentrated on colorectal, breast, and prostate cancers, with research and development efforts focused on the top 15 most lethal tumours, including multi-cancer testing. In 2009, the company established a partnership with the Mayo Clinic in Minnesota. In 2017, Exact Sciences won the Wisconsin Manufacturer of the Year award.

Exact Sciences stock is listed using the ticker EXAS on the NASDAQ. Exact Sciences Corporation stated in January 2021 that it has finalised its previously announced acquisition of Thrive Earlier Detection Corporation. Subsequently, in February 2021, Exact Sciences stated that it had entered into a deal with the Translational Genomics Research Institute (TGen), a City of Hope affiliate, to purchase Ashion Analytics, LLC (Ashion). Ashion is a CLIA-certified and CAP-accredited sequencing laboratory situated in Phoenix, Arizona. The company's genomics testing capabilities enable it to meet the increasingly complicated demands of clinical, academic, and biopharma clients focusing on precision cancer therapy.

Track EXAS stock with your eToro watchlist to receive news and price updates.